▎药明康德内容团队编辑

• 静息LVOT梯度与基线相比，在接受治疗48周后降低35.6 mmHg ± 32.6 mmHg，类似降低幅度维持至84周

• 血清NT-proBNP水平在接受治疗48周后平均降低480 ng/L。类似降低幅度维持至84周

• 在48周时，67.5%的患者与基线相比，纽约心脏协会（NYHA）功能分级改善1级以上。

参考资料：

[1] Bristol Myers Squibb Announces Data from EXPLORER-LTE Demonstrating Sustained Improvements in Clinically Meaningful Cardiovascular Outcomes at Weeks 48 and 84 in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy Receiving Mavacamten. Retrieved April 4, 2022, from https://investors.bms.com/iframes/press-releases/press-release-details/2022/Bristol-Myers-Squibb-Announces-Data-from-EXPLORER-LTE-Demonstrating-Sustained-Improvements-in-Clinically-Meaningful-Cardiovascular-Outcomes-at-Weeks-48-and-84-in-Patients-with-Symptomatic-Obstructive-Hypertrophic-Cardiomyopathy-Receiving-Mavacamten/default.aspx

[2] Mavacamten Demonstrated Significant Reduction in Need for Septal Reduction Therapy in Symptomatic Obstructive HCM Patients in Phase 3 VALOR Trial. Retrieved April 4, 2022, from https://investors.bms.com/iframes/press-releases/press-release-details/2022/Mavacamten-Demonstrated-Significant-Reduction-in-Need-for-Septal-Reduction-Therapy-in-Symptomatic-Obstructive-HCM-Patients-in-Phase-3-VALOR-Trial/default.aspx

版权说明：本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。